Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ: TLX)
The complaint alleges defendants made false and/or misleading statements and/or failed to disclose that: (1); Defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) Defendants materially overstated the quality of Telix’s supply chain and partners; and (3) as a result, Defendants’ statements about Telix’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.